Agios Pharmaceuticals (AGIO) Accumulated Expenses (2012 - 2026)

Agios Pharmaceuticals' Accumulated Expenses history runs 15 years deep, the most recent figure standing at $26.3 million for Q1 2026.

• Quarterly Accumulated Expenses rose 26.65% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (up 26.65% YoY) and the FY2025 annual result came in at $45.5 million, down 2.99% from the prior year.
• Accumulated Expenses was $26.3 million for Q1 2026 at Agios Pharmaceuticals, down from $45.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $46.9 million in Q4 2024 and bottomed at $19.7 million in Q1 2022.
• A 5-year average of $31.8 million and a median of $30.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses declined 21.28% — and 2023, when it jumped 42.23%.
• Agios Pharmaceuticals' Accumulated Expenses stood at $30.4 million in 2022, then soared by 42.23% to $43.2 million in 2023, then climbed by 8.56% to $46.9 million in 2024, then fell by 2.99% to $45.5 million in 2025, then plunged by 42.16% to $26.3 million in 2026.
• Business Quant data shows AGIO's Accumulated Expenses at $26.3 million in Q1 2026, $45.5 million in Q4 2025, and $37.2 million in Q3 2025.